缺血性脑卒中住院患者用药分析及其临床路径用药推荐

目的:对缺血性脑卒中住院患者的用药进行分析与推荐。方法:采用回顾性研究方法,对缺血性脑卒中住院患者病历进行用药分析,并基于缺血性脑卒中治疗指南等,对临床路径用药进行合理推荐。结果:缺血性脑卒中约89%的患者合并两种以上疾病。治疗药物使用比例排在前5位的依次为阿司匹林、阿托伐他汀钙、丹红、依达拉奉和桂哌齐特。不合理用药比例为9.93%,排在前3位的依次为用法用量不适宜、无特殊理由未按指南推荐用药和无适应证用药。患者平均用药费用1.11万元/人,占住院费用的49.33%。结论:缺血性脑卒中患者用药复杂,一些治疗药物使用的合理性缺少循证医学证据支持,临床路径用药方案需要完善,以提高其治疗的经济性。

Analysis on medication and clinical pathway medication recommendation in inpatients with cerebral infarction

Objective: To analyze and recommend medication in inpatients with cerebral infarction (CI).Methods:Via retrospective study method, medication analysis in inpatients with CI, and recommendations on clinical pathway were based on the guidelines and so on.Results:About 89% of patients with CI have two or more diseases. The top 5 drugs for the treatment are aspirin, atorvastatin calcium, Danhong, edaravone and cinepazide. Irrational drug use ratio is 9.93%, and the top 3 ones are inappropriate usage and administration route, no special reason for medication in compliance with the guidelines and no indication. The average cost of medicine was 11 100 yuan/person, accounting for 49.33% of the total cost.Conclusion: Various kinds of medications were used for the treatment of inpatients with CI, however the rationality of some drugs lacks evidence-based support. We should optimize clinical pathway medication regimensin order to improve medication cost-effectiveness.